Press Release | Thu Dec 20, 2012 8:30am EST

MSD Announces HPS2-THRIVE Study of TREDAPTIVE™ (modified-release nicotinic acid/laropiprant) Did Not Achieve Primary Endpoint

* Reuters is not responsible for the content in this press release.